Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03956680
Recruitment Status : Recruiting
First Posted : May 21, 2019
Last Update Posted : December 3, 2020
Sponsor:
Information provided by (Responsible Party):
Bristol-Myers Squibb

Brief Summary:
The main purpose of this study is to characterize the safety, tolerability, dose limiting toxicities, best route of administration, maximum tolerated dose, maximum administered dose, or alternative dose of BMS-986301 alone or in combination with nivolumab and ipilimumab in participants with cancers that have failed to respond to T cell checkpoint inhibiting antibodies.

Condition or disease Intervention/treatment Phase
Advanced Solid Cancers Drug: BMS-986301 Biological: Nivolumab Biological: Ipilimumab Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 190 participants
Allocation: N/A
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study of BMS-986301 Monotherapy and Combination Therapy With Nivolumab and Ipilimumab in Participants With Advanced Solid Cancers
Actual Study Start Date : March 26, 2019
Estimated Primary Completion Date : November 20, 2022
Estimated Study Completion Date : July 1, 2024

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Part 1A Group 1: BMS-986301 Monotherapy Intramuscular (IM) Drug: BMS-986301
Specified dose on specified days

Biological: Nivolumab
Specified dose on specified days
Other Name: OPDIVO

Biological: Ipilimumab
Specified dose on specified days
Other Name: YERVOY

Experimental: Part 1A Group 2: BMS-986301 Monotherapy Intratumoral (I-TUMOR) Sub-study Drug: BMS-986301
Specified dose on specified days

Biological: Nivolumab
Specified dose on specified days
Other Name: OPDIVO

Biological: Ipilimumab
Specified dose on specified days
Other Name: YERVOY

Experimental: Part 1A Group 3: BMS-986301 Monotherapy Intravenous (IV) Sub-study Drug: BMS-986301
Specified dose on specified days

Biological: Nivolumab
Specified dose on specified days
Other Name: OPDIVO

Biological: Ipilimumab
Specified dose on specified days
Other Name: YERVOY

Experimental: Part 1B Group 4: Systemic BMS-986301 + Nivolumab + Ipilimumab Drug: BMS-986301
Specified dose on specified days

Biological: Nivolumab
Specified dose on specified days
Other Name: OPDIVO

Biological: Ipilimumab
Specified dose on specified days
Other Name: YERVOY

Experimental: Part 1B Group 5: I-TUMOR BMS-986301 + Nivolumab + Ipilimumab Drug: BMS-986301
Specified dose on specified days

Biological: Nivolumab
Specified dose on specified days
Other Name: OPDIVO

Biological: Ipilimumab
Specified dose on specified days
Other Name: YERVOY




Primary Outcome Measures :
  1. Incidence of dose-limiting toxicity (DLTs) [ Time Frame: Cycle 1 (28 days) ]
  2. Incidence of adverse events (AEs) [ Time Frame: From Baseline until study exit (up to approximately 2 years) ]
  3. Incidence of serious adverse events (SAEs) [ Time Frame: From Baseline until study exit (up to approximately 2 years) ]
  4. Incidence of AEs leading to discontinuation [ Time Frame: From Baseline until study exit (up to approximately 2 years) ]
  5. Incidence of deaths [ Time Frame: From Baseline until study exit (up to approximately 2 years) ]
  6. Incidence of clinically significant changes in clinical laboratory results: Hematology tests [ Time Frame: From Baseline until disease progression (approximately 2 years) ]
  7. Incidence of clinically significant changes in clinical laboratory results: Clinical Chemistry tests [ Time Frame: From Baseline until disease progression (approximately 2 years) ]
  8. Incidence of clinically significant changes in clinical laboratory results: Urinalysis tests [ Time Frame: From Baseline until disease progression (approximately 2 years) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

  • Histologically or cytologically confirmed advanced unresectable/metastatic malignancy of the squamous cell carcinoma of the head and neck (HNSCC), non-small cell lung cancer (NSCLC), melanoma, renal cell carcinoma (RCC), triple negative breast cancer (TNBC), and urothelial carcinoma (UCC), that are refractory to or intolerant of existing therapy(ies) known to provide clinical benefit for the condition of the participant
  • Must have experienced radiographically documented progressive disease on or after the most recent therapy
  • Eastern Cooperative Oncology Group (ECOG) score of 0 or 1
  • Women and men must agree to follow specific methods of contraception, if applicable, while participating in the trial

Exclusion Criteria:

  • Primary central nervous system (CNS) malignancy
  • Other active malignancy requiring concurrent intervention
  • Uncontrolled or significant cardiovascular disease

Other protocol defined inclusion/exclusion criteria could apply


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03956680


Contacts
Layout table for location contacts
Contact: Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, Please email: Clinical.Trials@bms.com
Contact: First line of the email MUST contain NCT # and Site #.

Locations
Layout table for location information
United States, Illinois
The University of Chicago Medicine Recruiting
Chicago, Illinois, United States, 60637
Contact: Randy Sweis, Site 0003    773-702-1835      
United States, Missouri
Washington University School OF Medicine-Siteman Cancer Center Recruiting
Saint Louis, Missouri, United States, 63110
Contact: Tanner Johanns, Site 0005    314-362-4140      
United States, Pennsylvania
UPMC Hillman Cancer Center Recruiting
Pittsburgh, Pennsylvania, United States, 15232-1305
Contact: Jason Luke, Site 0006    412-623-6121      
United States, Texas
MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Filip Janku, Site 0002    713-745-4297      
Canada, Ontario
Local Institution Recruiting
Toronto, Ontario, Canada, M5G 1Z5
Contact: Site 0001         
Sponsors and Collaborators
Bristol-Myers Squibb
Investigators
Layout table for investigator information
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
Additional Information:
Layout table for additonal information
Responsible Party: Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT03956680    
Other Study ID Numbers: CA046-006
2018-003610-41 ( EudraCT Number )
First Posted: May 21, 2019    Key Record Dates
Last Update Posted: December 3, 2020
Last Verified: November 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Nivolumab
Ipilimumab
Antineoplastic Agents, Immunological
Antineoplastic Agents